ArticleHereditas2025
Qushi huayu decoction dose-dependent inhibition of caspase-2/SREBP-1 in MASLD mice.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is characterized by hepatic lipid accumulation and metabolic disturbances. Caspase-2 cleaves site-1 protease (S1P), leading to the persistent activation of sterol regulatory element-binding proteins (SREBPs), which subsequently promote the progression of MASLD. Previous studies have demonstrated that the Qushi Huayu Decoction (QHD) significantly alleviates MASLD, particularly inhibiting the expression of SREBP-1 in hepatocytes of MASLD mouse models. However, its regulatory effect on the Caspase-2/SREBP-1 pathway and the dose-dependent nature of these effects remain unclear.
objectiveThe regulatory effects of high, medium, and low doses of Qushi Huayu Decoction (QHD) on the Caspase-2/SREBP-1 pathway and their potential dose-dependent impacts was investigated.
methodA MASLD model was induced in 28-week-old C57BL/6J mice using a high-fat diet (HFD). Mice were treated with QHD granules at high (3.466 g/kg), medium (1.733 g/kg), and low doses (0.867 g/kg), as well as a Caspase-2 inhibitor for a duration of 5 weeks. Pharmacodynamic indicators, including triglycerides (TG) and free fatty acids (FFA) in liver tissue, hepatic histopathology, and serum biochemical markers, were assessed. The expression of genes in the Caspase-2/SREBP-1 signaling pathway and its downstream targets was also analyzed.
resultsQHD at all doses effectively improved hepatic steatosis. The low-dose group significantly reduced hepatic TG levels (p < 0.01) and the insulin resistance index (p < 0.05). The high-dose group significantly inhibited the expression of Caspase-2 protein (p < 0.01) and nuclear SREBP-1 protein (p < 0.05), with a dose-dependent decrease in Caspase-2 activity.
conclusionQHD exhibits dose-dependent, complementary effects in MASLD, with low doses improving lipid metabolism and insulin sensitivity, and high doses more effectively suppressing Caspase-2/SREBP-1 and inflammatory signaling. This dual action underscores its broad regulation of ER stress and supports stage-specific, hierarchical dosing strategies aligned with traditional Chinese medicine principles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.